All News

Patients with only dry eye had less severe lid margin abnormalities and orifice plugging along with tear film instability compared with those who were diagnosed with both dry eye and diabetes.

The Supreme Court decision in Medina v Planned Parenthood interprets the Social Security Acts Medicaid provision as not being able to be enforced by an individual, according to Jennifer Evans, JD.

Metformin use may enhance progression-free survival (PFS) in patients receiving first-line systemic therapy for patients with metastatic colorectal cancer.

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a higher percentage of regulatory T cells (Tregs).

July is UV Safety Awareness Month, highlighting the growing risks of UV radiation and encouraging the use of protective measures to reduce sun-related health threats.

Researchers said longitudinal studies are critical to refine and optimize the management of metabolic dysfunction–associated steatotic liver disease (MASLD).

AZD0486 demonstrated encouraging safety and dose-dependent efficacy in heavily pretreated adolescent and adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), according to early findings from the phase 1/2 SYRUS trial and Ibrahim Aldoss, MD, of City of Hope.

This new study identifies key contributors to mental health decline in individuals with atopic dermatitis, highlighting the need for integrated care.

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with significant health benefits.

While artificial intelligence (AI) holds promise to improve the diagnosis of melanoma, researchers of a new review outlined challenges with these novel approaches.

The platform technology designation is a new designation established by the FDA.

Imetelstat demonstrated clinical benefits in patients with ring sideroblast–negative lower-risk MDS, according to a post hoc analysis.

The recent increase in prolonged emergency department (ED) stays and boarding times for older adults reveals systemic challenges in US hospital care.

High infection rates among younger adults suggest they either delay routine dental care and only seek treatment when conditions become severe, or face more barriers.

The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.

Increasing environmental events driven by climate change and human activity exacerbate allergy and asthma conditions, further compounded by exposure to persistent pollutants like per-and polyfluoroalkyl substances and microplastics.

From the impact of rising grocery prices to disparities in myeloma outcomes, check out news from the Center on Health Equity & Access this past week.

Making pre-exposure prophylaxis (PrEP) more accessible can help to decrease the incidence of HIV in the US.

Artificial intelligence (AI)–based electrocardiogram interpretation (AI-ECG) detected left ventricular systolic dysfunction (LVSD) in patients with muscular dystrophy, a recent study found.

In myasthenia gravis, complement plays a big role in what happens to the muscle end of the neuromuscular junction, explains Miriam Freimer, MD, an author on 5 abstracts presented at the recent 15th MGFA International Conference on Myasthenia and Related Disorders.

A new economic evaluation supports updating rheumatoid arthritis guidelines to favor biosimilar disease-modifying antirheumatic drugs over leflunomide after methotrexate failure.

Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.

FDA issues a complete response letter for oxylanthanum carbonate, a treatment for hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.

Researchers called for standardized health outcome descriptors to help bridge communication gaps in rheumatology care and improve shared decision-making.

The findings suggest a role for assessment of variant-carrying status to predict disease progression in idiopathic pulmonary fibrosis (IPF).

A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering a practical strategy that does not compromise efficacy.

Disparities in multiple myeloma outcomes and the need for equitable care were the focus of 2 posters presented at the 2025 American Society of Clinical Oncology annual meeting.

Ibrahim Aldoss, MD, discusses the potential of AZD0486 for treating relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and outlines the SYRUS study objectives.

A post-hoc analysis of the phase 3b JUMP trial found that ruxolitinib plus anemia supportive care maintained efficacy and reduced transfusion needs in patients with myelofibrosis.

In the M-ACCEL trial, HU6-induced weight loss was exclusively attributed to fat loss, with no statistically significant loss in lean muscle.